SCGB1A1 as a Key Regulator of Splenic Immune Dysfunction in COPD: Insights From a Murine Model

Area of Science:

• Immunology
• Pulmonology
• Pathology

Background:

• Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease with systemic immune consequences.
• COPD patients exhibit heightened susceptibility to sepsis and septic shock.
• Understanding COPD's impact on splenic immune function is crucial for managing sepsis risk.

Purpose of the Study:

• To investigate the effects of a rat COPD model on splenic function.
• To identify molecular mechanisms underlying COPD-associated splenic immune dysfunction.
• To evaluate the role of secretoglobin family 1a member 1 (SCGB1A1) in modulating immune responses within the spleen.

Main Methods:

• Established a rat model of COPD using lipopolysaccharide (LPS) and chronic cigarette smoke exposure.
• Assessed splenic phagocytic capacity via carbon clearance assays.
• Performed histological analysis and high-throughput mRNA sequencing of splenic tissues.
• Utilized in vitro assays to examine SCGB1A1's effect on macrophage activation and lymphocyte proliferation.

Main Results:

• COPD model rats showed significantly reduced splenic phagocytic activity.
• Histological examination revealed splenic lymphoid follicle atrophy and connective tissue hyperplasia.
• mRNA sequencing identified SCGB1A1 as significantly upregulated in smoke-exposed rats.
• In vitro studies demonstrated SCGB1A1 inhibits LPS-induced macrophage activation and PHA-induced lymphocyte proliferation.

Conclusions:

• SCGB1A1 plays a role in splenic immune dysfunction observed in COPD.
• Elevated SCGB1A1 expression contributes to impaired splenic immune responses in COPD.
• Targeting SCGB1A1 in the spleen may offer a therapeutic strategy to mitigate sepsis risk in COPD patients.